IP Library › Granted Patent US 10,870,657
Granted Patent B2
US 10,870,657 · App. 16/246,027 · Granted Dec 22, 2020

Compounds for the treatment of cancer and inflammatory disease

Inventors: Yaron R. Hadari (Harrison, NY); Luca Carta (Hartsdale, NY); Michael Schmertzler (New Canaan, CT); Theresa M. Williams (Harleysville, PA); Charles H. Reynolds (Austin, TX)
Assignee: SHY Therapeutics LLC
C07D495/04C07D221/04C07D239/94C07D265/30C07D271/06C07D401/04C07D401/12C07D401/14C07D407/14C07D409/14C07D413/14C07D417/14C07D471/04C07D473/30C07D487/04C07D495/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,870,657
App. No.
16/246,027
Granted
Dec 22, 2020
Kind
B2
Abstract

Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.

Claims (12)

1. A compound of Formula VIIIb1:

or a pharmaceutically acceptable salt thereof,

wherein R 1b1 is 2-pyridyl;

R 8b1 is H;

R 9b1 is halo;

R 6b1 and R 7b1 are combined to form a cyclic structure including the nitrogen atom to which they are both attached.

2. A method of treating cancer, comprising administering to a subject the compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the cancer is a solid tumor, and said solid tumor is hepatocellular carcinoma, prostate cancer, pancreatic cancer, ovarian cancer, or glioblastoma.

3. The method of claim 2 , wherein the solid tumor is pancreatic cancer.

4. A method of treating an inflammatory disease, comprising administering to the compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the inflammatory disease is inflammatory bowel disease, Barrett's esophagus, asbestosis, gingivitis, pancreatitis, or bronchitis.

5. A pharmaceutical composition, comprising a therapeutically effective amount of the compound of Formula VIIIb1 of claim 1 and a pharmaceutically acceptable carrier.

6. The compound of claim 1 , wherein the compound is:

7. A pharmaceutical composition, comprising a therapeutically effective amount of the compound of claim 6 and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2019
From: SCHMERTZLER, MICHAEL; HADARI, YARON R.; REYNOLDS, CHARLES H.; WILLIAMS, THERESA M.; CARTA, LUCA
To: SHY THERAPEUTICS LLC
Reel/Frame 048678/0577 →
Continuity (3)
Continuation 15387349 · Dec 21, 2016
Provisional Application 62271185 · Dec 22, 2015
Related Publication 20190218229A1 · Jul 18, 2019
Cited By (4)
US 12,391,705 US 12,435,046 US 12,653,810 US 12,714,713